Initially, it remains an effective and essential paradigm in the treatment of metastatic CRPC, but AR reactivation drives prostate cancer to lethal CRPC phenotype in all patients despite effective testosterone suppression[16]. The gene discussed is AR; the disease is prostate cancer.